This announcement is a separate document:
泰恩康：关于全资子公司盐酸毛果芸香碱滴眼液III期临床试验完成全部受试者入组的公告
Taienkang: Announcement on the completion of phase III clinical trial of pilocarpine hydrochloride eye drops, a wholly-owned subsidiary
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.